Literature DB >> 9366336

Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.

W J Catalona1, J A Beiser, D S Smith.   

Abstract

PURPOSE: We examined the usefulness of measurements of free prostate specific antigen (PSA) and PSA density for predicting prostate cancer in men who had had a prior negative biopsy, a serum PSA level of 4.1 to 10.0 ng./ml. and benign findings on prostate examination.
MATERIALS AND METHODS: We measured percent free serum PSA and PSA density in 163 male volunteers age 50 years or older who were advised to have repeat prostatic biopsies for a serum PSA level of 4.1 to 10.0 ng./ml.
RESULTS: Of 99 men who had repeat biopsies 20 (20%) had prostate cancer detected. Prostate cancer was significantly associated with lower free PSA level and higher PSA density, with overlap in 83% of the cases. The use of percent free PSA cutoffs of 28 and 30% would have detected 90 and 95% of cancers, respectively, and avoided 13 and 12% of the biopsies, respectively. PSA density cutoffs of 0.10 and 0.08 would have detected 90 and 95% of cancers, respectively, and avoided 31 and 12% of biopsies, respectively.
CONCLUSIONS: Free PSA and PSA density predict prostate cancer in men who have had prior negative prostatic biopsies, serum PSA levels of 4.1 to 10.0 ng./ml. and a benign prostate examination. Both parameters may be used to avoid unnecessary biopsies with an acceptable decrease in sensitivity. Further studies are needed to determine cutoffs to be used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366336     DOI: 10.1016/s0022-5347(01)68187-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

Authors:  Peter H Gann; Angela Fought; Ryan Deaton; William J Catalona; Edward Vonesh
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

2.  A 49-year-old Hispanic male with intraepithelial neoplasia and focal atypia.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

3.  Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.

Authors:  Hyesook Yoon; Sachiko I Blaber; Wu Li; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

4.  Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.

Authors:  Necati Muşlu; Bahadır Ercan; Serin Akbayır; Şenay Balcı; H Didem Ovla; Murat Bozlu
Journal:  Turk J Urol       Date:  2017-01-06

5.  Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.

Authors:  Christian Pfister; Jean-Pierre Basuyau
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

6.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

Review 7.  PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.

Authors:  Sema Nur Ayyıldız; Ali Ayyıldız
Journal:  Turk J Urol       Date:  2014-06

Review 8.  [Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].

Authors:  J Palisaar; T Eggert; M Graefen; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

9.  A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.

Authors:  Hyesook Yoon; Sachiko I Blaber; Mekdes Debela; Peter Goettig; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2009-04       Impact factor: 3.915

Review 10.  Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

Authors:  S Jain; A G Bhojwani; J K Mellon
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.